Safety and efficacy of allopurinol in chronic kidney disease (Q38164653)

30 August 2017

Safety and efficacy of allopurinol in chronic kidney disease (English)

1 reference

30 August 2017

1 reference

Maria Miller Thurston

series ordinal

1

1 reference

30 August 2017

Beth Bryles Phillips

series ordinal

2

1 reference

30 August 2017

Catherine A Bourg

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

9 October 2013

1 reference

Annals of Pharmacotherapy

30 August 2017

1 reference

30 August 2017

47

1 reference

30 August 2017

1507-1516

1 reference

30 August 2017

11

1 reference

30 August 2017

Clinical practice. Gout

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Long-term use of allopurinol in the treatment of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Management of gouty arthritis in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Chronic kidney disease in gout in a managed care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Managing gout: how is it different in patients with chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Clinical risk factors for adverse events in allopurinol users

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Relation between adverse events associated with allopurinol and renal function in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Challenges of conducting a trial of uric-acid-lowering therapy in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504740

21 January 2018

Identifiers

DOI

10.1177/1060028013504740

1 reference

30 August 2017

1 reference